(RTTNews) - The Indonesia stock market has finished lower in three straight sessions, sinking more than 300 points or 4.2 percent in that span. The Jakarta Composite Index now sits just above the 7,130-point plateau and it's tipped to open in the red again on Monday. The global forecast for the Asian markets is soft on continuing concerns over the war in the Middle East and the resulting surge in ...
(RTTNews) - The Indonesia stock market has finished lower in three straight sessions, sinking more than 300 points or 4.2 percent in that span. The Jakarta Composite Index now sits just above the 7,130-point plateau and it's tipped to open in the red again on Monday. The global forecast for the Asian markets is soft on continuing concerns over the war in the Middle East and the resulting surge in oil prices. The European and U.S. markets were down and the Asian bourses are expected to follow to the downside. The JCI finished sharply lower on Friday with damage across the board, especially among the financial, resource, cement, food and telecom sectors. For the day, the index cratered 224.91 points or 3.05 percent to finish at 7,137.21 after trading between 7,132.21 and 7,350.28. Among the actives, Bank CIMB Niaga shed 0.57 percent, while Bank Mandiri stumbled 4.23 percent, Bank Danamon Indonesia declined 1.58 percent, Bank Negara Indonesia dropped 0.93 percent, Bank Central Asia fell 0.36 percent, Bank Rakyat Indonesia retreated 1.68 percent, Indosat Ooredoo Hutchison plunged 6.54 percent, Indocement contracted 2.70 percent, Semen Indonesia slumped 2.35 percent, Indofood Sukses Makmur skidded 2.48 percent, United Tractors sank 3.00 percent, Astra International tumbled 2.10 percent, Energi Mega Persada crashed 3.75 percent, Aneka Tambang lost 2.06 percent, Vale Indonesia plummeted 6.22 percent, Timah tanked 4.51 percent, Bumi Resources cratered 3.67 percent and Astra Agro Lestari was unchanged. The lead from Wall Street is weak as the major averages opened higher on Friday but turned lower as the day progressed, slipping into the red and finishing at session lows. The Dow dropped 119.43 points or 0.26 percent to finish at 46,558.47, while the NASDAQ tumbled 206.64 points or 0.93 percent to close at 22,105.36 and the S&P 500 sank 40.43 points or 0.61 percent to end at 6,632.19. For the week, the Dow plunged 2.0 percent, the S&P dropped 1.6 percent and the NASDAQ slump...
After the annual “ two sessions ” in Beijing, it’s clear that Hong Kong policymakers have their work cut out for them. It has been made abundantly clear what is expected of Hong Kong: stop messing around and get on with the national programme. Hong Kong is part of the nation’s plans to move forward. The country knows exactly where the city fits into the big picture, how it can catapult growth in k...
After the annual “ two sessions ” in Beijing, it’s clear that Hong Kong policymakers have their work cut out for them. It has been made abundantly clear what is expected of Hong Kong: stop messing around and get on with the national programme. Hong Kong is part of the nation’s plans to move forward. The country knows exactly where the city fits into the big picture, how it can catapult growth in key areas and play the role of superconnector between China and the rest of the world. The 15th five-year plan outlined the city’s task of building a commodity trading ecosystem, a high-quality supply chain service centre and a global talent hub. Beijing has reiterated its support for Hong Kong to continue its drive to not only be an international finance centre but to be the centre for shipping, trade, aviation, and innovation and technology. The Northern Metropolis is still on Beijing’s radar. Advertisement Chief Executive John Lee Ka-chiu has pledged to align with the national strategies and reiterated that his administration will hash out the city’s plan. Lee said he would get that job done before the end of the year and lead all bureaus to complete the plan. Lee has a lot on his plate; we can’t possibly expect him to be hands-on with everything. Hong Kong runs on an executive-led system, but it cannot be a system where things only get done if the chief executive personally leads and oversees everything. Politburo Standing Committee members Ding Xuexiang (left) and Wang Huning chat during the opening session of the National People’s Congress in Beijing, on March 5. Photo: AP Beijing knows this. Chinese Vice-Premier Ding Xuexiang has emphasised that implementing an executive-led governance system in Hong Kong is a “shared responsibility”. The legislative and judicial branches, and society as a whole, must support the model.
Swati Pradhan sees about 12 obesity patients a day at her small clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S ’s blockbuster weight-loss drug at half the price. The Danish drugmaker’s key patent on semaglutide, the active ingredient in Ozempic and Wegovy that reshaped the global ...
Swati Pradhan sees about 12 obesity patients a day at her small clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S ’s blockbuster weight-loss drug at half the price. The Danish drugmaker’s key patent on semaglutide, the active ingredient in Ozempic and Wegovy that reshaped the global weight-loss industry, expires in India on March 20 . At least five Indian drugmakers — Mankind Pharma Ltd. , Ajanta Pharma Ltd. , Sun Pharmaceutical Industries Ltd. , Dr. Reddy’s Laboratories Ltd. , and Lupin Ltd. — are gearing up to sell cheaper copies of the drug immediately after the expiry, according to their statements and post-earnings calls . This has prompted hospitals, telehealth firms and clinics across India to expand obesity-focused services in anticipation of a demand surge. The generic versions are expected to be at least 50% cheaper — priced at around 5,000 rupees ($54) for a weekly dose — than Novo’s therapy, according to people familiar with the matter who spoke on the condition of anonymity as pricing information is competitive. India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions. With its large disease burden and an entrenched pharmaceutical industry known for copycat drugs, India is set to be the test case for how much the prices of these anti-obesity drugs can plummet. Metabolic disorders such as thyroid disease, diabetes and fatty liver have surged among India’s 1.4-billion-plus population, largely due to increasingly sedentary urban lifestyles. On the other hand, high-calorie diets , dripping with oil and fat, have contributed to rising weight gain in the country, which has the world’s third-largest overweight population , trailing the US and China. Read More: Generic Ozempic Makers Are Coming to Upend the Obesity Market In a move aimed at curbing aggressive commercial ...
In this article CAAS USO MCHI USB Follow your favorite stocks CREATE FREE ACCOUNT U.S. President Donald Trump prepares to greet Chinese President Xi Jinping ahead of a bilateral meeting at Gimhae Air Base on October 30, 2025 in Busan, South Korea. Andrew Harnik | Getty Images U.S. President Donald Trump said his planned trip to China later this month could be delayed as Washington sought to pressu...
In this article CAAS USO MCHI USB Follow your favorite stocks CREATE FREE ACCOUNT U.S. President Donald Trump prepares to greet Chinese President Xi Jinping ahead of a bilateral meeting at Gimhae Air Base on October 30, 2025 in Busan, South Korea. Andrew Harnik | Getty Images U.S. President Donald Trump said his planned trip to China later this month could be delayed as Washington sought to pressure Beijing to help reopen the Strait of Hormuz, underscoring a renewed flashpoint in an already fragile bilateral relationship. In an interview with the Financial Times on Sunday, Trump said he expected China to help unblock the strait before he travels to Beijing for a summit with Chinese leader Xi Jinping , which had been scheduled for March 31 to April 2 . Trump added that the two weeks to the meeting were a "long time" and that Washington wanted clarity before then. "We may delay," Trump told the FT, without elaborating on timing. The remarks came as Treasury Secretary Scott Bessent met his Chinese counterpart He Lifeng in Paris for talks about the planned summit. Beijing has yet to confirm the dates and typically announces such plans closer to their scheduled start. The visit would be the first for a U.S. president since Trump's last trip during his first term in 2017. It also comes five months after the two leaders met in the South Korean city of Busan, where they agreed to a one-year truce in a trade war that had seen tit-for-tat tariffs briefly soar to triple-digit levels last year. Chinese top diplomat Wang Yi said earlier this month that the agenda for the exchange was already "on the table." Trump said Sunday aboard Air Force One that China sourced about 90% of its oil through the strait, framing Beijing's cooperation on Hormuz as a matter of self-interest. The president has appealed to several European and Asian countries, including China, to help open up the chokepoint through which roughly one-fifth of the world's daily oil supply passes. However, the numbers ...
This month, nuclear energy companies Oklo (OKLO 2.11%) and Centrus Energy (LEU 2.41%) have agreed to pursue discussions on a joint venture focused on deconversion services for high-assay, low-enriched uranium (HALEU), as well as advancing related supply chains and fuel-cycle technologies. These two companies figure to play prominent roles as the United States expands its nuclear energy capabilitie...
This month, nuclear energy companies Oklo (OKLO 2.11%) and Centrus Energy (LEU 2.41%) have agreed to pursue discussions on a joint venture focused on deconversion services for high-assay, low-enriched uranium (HALEU), as well as advancing related supply chains and fuel-cycle technologies. These two companies figure to play prominent roles as the United States expands its nuclear energy capabilities, but if you are considering investing, one stands out as a better buy today. Oklo's reactors require next-generation nuclear fuel Oklo is an early-stage nuclear energy company that develops advanced fission power plants called Aurora powerhouses. These powerhouses are built on liquid-metal cooled-sodium fast reactor technology based on the Experimental Breeder Reactor-II (EBR-II), which operated for over 30 years at the Idaho National Laboratory (INL) before being shut down in 1994. In January, Oklo entered an agreement with Meta Platforms to develop a 1.2 gigawatt (GW) power campus in Ohio. As part of the agreement, Meta will prepay for power, providing Oklo with upfront capital to advance the project. The first phase is targeted for 2030, and it will eventually scale up to the full 1.2 GW capacity by 2034. Expand NYSE : OKLO Oklo Today's Change ( -2.11 %) $ -1.26 Current Price $ 58.33 Key Data Points Market Cap $9.1B Day's Range $ 57.96 - $ 61.68 52wk Range $ 17.42 - $ 193.84 Volume 162K Avg Vol 10M Oklo's Aurora powerhouses use high-assay, low-enriched uranium, a next-generation nuclear fuel with enrichment levels higher than that of traditional low-enriched uranium (LEU) used in today's nuclear power plants. You can think of it as premium fuel for next-generation microreactors. This is where Centrus comes into the picture. The company is the only one with an enrichment facility approved by the Nuclear Regulatory Commission to produce HALEU enriched up to 20%, giving it a first-mover advantage. Currently, Centrus procures low-enriched uranium (LEU) used in today's reac...
Key Points Oklo develops advanced Aurora powerhouses that require next-generation nuclear fuel (HALEU). Centrus is the only company with an approved facility for HALEU production. 10 stocks we like better than Oklo › This month, nuclear energy companies Oklo (NYSE: OKLO) and Centrus Energy (NYSE: LEU) have agreed to pursue discussions on a joint venture focused on deconversion services for high-as...
Key Points Oklo develops advanced Aurora powerhouses that require next-generation nuclear fuel (HALEU). Centrus is the only company with an approved facility for HALEU production. 10 stocks we like better than Oklo › This month, nuclear energy companies Oklo (NYSE: OKLO) and Centrus Energy (NYSE: LEU) have agreed to pursue discussions on a joint venture focused on deconversion services for high-assay, low-enriched uranium (HALEU), as well as advancing related supply chains and fuel-cycle technologies. These two companies figure to play prominent roles as the United States expands its nuclear energy capabilities, but if you are considering investing, one stands out as a better buy today. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Oklo's reactors require next-generation nuclear fuel Oklo is an early-stage nuclear energy company that develops advanced fission power plants called Aurora powerhouses. These powerhouses are built on liquid-metal cooled-sodium fast reactor technology based on the Experimental Breeder Reactor-II (EBR-II), which operated for over 30 years at the Idaho National Laboratory (INL) before being shut down in 1994. In January, Oklo entered an agreement with Meta Platforms to develop a 1.2 gigawatt (GW) power campus in Ohio. As part of the agreement, Meta will prepay for power, providing Oklo with upfront capital to advance the project. The first phase is targeted for 2030, and it will eventually scale up to the full 1.2 GW capacity by 2034. Oklo's Aurora powerhouses use high-assay, low-enriched uranium, a next-generation nuclear fuel with enrichment levels higher than that of traditional low-enriched uranium (LEU) used in today's nuclear power plants. You can think of it as premium fuel for next-generation microreactors. This is where Centrus comes into the picture. The compa...